Promoting the Economic, Environmental, Health and Social Benefits of a NZ Hemp Industry

News

1 2 3 5

Public Newsletter May and June 2018

Public Newsletter  May and June 2018

NZ Hemp Industries Association Inc, 1997
Promoting the Economic, Environmental, Health & Social Benefits of a New Zealand Hemp Industry

Public Newsletter for June 2018

In this issue:

  • MPI Hemp seed food update and fit for purpose review

  • The iHemp Summit, Wellington, 5 & 6th July 2018

  • WHO World Health Organisation, Special meeting on cannabis and related substances 4-7 June 2018

  • Events and iHemp Press Articles

HH Hemp Ltd, Kompolti crop, Dunedin 2017/2018

MPI Hemp Seed Food Update and Fit for
Purpose Review – Send in your response now

The much anticipated MPI discussion document on the April 2017 variation to the food code, was finally released on May 10, with responses due by 20th June 2018.

Due to the delay in getting the discussion document out for public consultation, New Zealand will not have a green light for human consumption of hemp seed, until latter this year or early 2019!.

When it finally happens it will be great news for the consumers but it will be too late for the industry to scale up and plant more seed crops this season.

The approach in the discussion document is significantly incorrect and these shortcomings need to be raised with MPI and MOH

The NZHIA have prepared a response (copy here) which highlights the simple approach, we recommend to allowing hemp seed foods within the Food Act.  Hemp food products are already covered as “Hemp Products” in the iHemp Regulations, so there is no need to amend our regulations.  MPI simply have to incorporate the April 2017 variation in to the NZ Food Act 2015 and the job is done!,

We encourage you to email your feedback on the discussion document by 5pm on 20 June 2018 to food.policy@mpi.govt.nz  Please let them know “we support the feedback document provided by the NZHIA ” and add your own comments and recommendations, we have provided some ideas here.

The “fit for purpose” review has missed all of industry’s concerns, which have been raised over the last 10 years.  Instead of helping to enable the industry, MPI have followed the lead of MOH who want to add more control in to the iHemp Regulations, with recommendations that achieve very little and are not actually required.

The MOH are confused and need to reconsider their intent and interpretation of the regulations rather than making changes to them.

We applaud MPI for taking the initiative and trying to get a “fit for purpose” review done as part of the process to allow hemp seed for human consumption.  However it could delay the food issue as the changes proposed by MOH are unacceptable to many in the iHemp industry.

MPI need to keep it simple and separate the two issues and get the food access sorted with urgency.  Then encourage MOH to listen to industry and make the iHemp Regulations work as they were intended, and enable the development of a great new industry for New Zealand.

New Zealand’s inaugural – iHemp Summit – 5th to 6th July, Wellington.  With a welcome evening reception on the 4th

The Program is now available on hempsummit.nz

Come along and learn about the industry and what is needed to move the economic, environmental and social potential of iHemp, forward .

The number of tickets is limited, so get in now to ensure you don’t miss out on the first iHemp Summit in New Zealand.

Check out hempsummit.nz  and face book hempsummit.nz

Please pass this on to people in your networks who should be aware of iHemp and the event.

World Health Organisation (WHO) meeting of the Expert Committee on Drug Dependence (ECCD), Geneva 4-7 June 2018

The 40th ECDD meeting, is a specially convened session dedicated to carrying out reviews of cannabis and cannabis-related substances:

  1. Preparations containing cannabidiol (CBD)
  2. Cannabis plant and cannabis resin
  3. Extracts and tinctures of cannabis*
  4. Delta-9-tetrahydrocannabinol (THC)
  5. Isomers of THC.
After the open session on the afternoon of Monday the 4th June, there is a two day closed session.The closed session will begin with, updates on priorities of international agencies and an overview of the current status of cannabis control within international drug control conventions.

Following this will be a critical review of 1 above, 2-5 are pre-reviews, all of which involve presentations of “key points from report”, “country questionnaires” and “peer reviews” and a panel discussion.

The outcome will be a –  “Review and Adoption of Final Report”

The Misuse of Drugs – Medicinal Cannabis Amendment Bill
Hear the submissions on the Health Select Committee Facebook page

Recent iHemp – New Zealand press articles

Idealog – Green Rush a new series on the emerging cannabis industry
30 May 2018 – Hemp Summit taps growing interest
26 May 2018 – New Zealand hemp industry set for exciting boom
24 May 2018 – Cannabis firm has high hopes
23 May 2018  – Summit looks at $75b industry
21 May 2018  – Cannabis companies to put themselves in ‘best light’ at inaugural summit
20 May 2018 – Cannabis Inc
15 May 2018 – Hemp farmers are ready to plant
10 May 2018 – Medicinal cannabis company’s investment round crashes crowdfunding site
2 May 2018 – cannabis bill too strict for NZ growers

23 Mar 2018 – Hemp innovation hub to be launched in Rotorua

International Events

2 – 5 November 2018 – 25 HIA Annual Conference, Los Angeles

16-17 October 2018  – 8th international Hemp Building Symposium, Brussels, Belgium

Join the NZHIA for more information and support for your hemp enterprise, together we stand!

MPI Consultation – Food and the iHemp Regulations

MPI Consultation closes 20 June 2018

The industry and all interested parties need to send an email today!

YOU CAN MAKE A DIFFERENCE, 10 days before the deadline and MPI have received only 2 responses!

 

It you want an iHemp industry this is a great opportunity to show MPI we are serious, please email Food.Policy@mpi.govt.nz and send them your views, we have provided some ideas below

 

The MPI discussion document has combined two issues:

  • Allowing hemp seed food for human consumption
  • “Fit for purpose” review of the iHemp Regulations 2006

This has caused a lot of confusion as the food issue is simple and the review is a lot more involved.

The NZHIA have given MPI our comments and recommendations, a copy can be found here.

The Hemp seed food variation is an MPI-Food issue and can be handled quickly. 

The MOH review of the iHemp Regs will take longer as most of the changes they recommend are unacceptable. 

MOH need help to understand the iHemp industry and this should not delay access to hemp seed foods, we have already waited 18 years!!

We need you to contribute to the discussion and email Food.Policy@mpi.govt.nz before the 20th June

 

To whom it may concern,
RE: Proposed changes to the Misuse of Drugs (Industrial Hemp) Regulations 2006 and regulations under the Food Act 2014.

….. Then give your thoughts on the following ;

….  Don’t forget to add your, name and company name if relevant and your  address

 

Some ideas of what to include:

We support the comments and recommendations made by the NZHIA

Keep it simple and keep the food issue separate, and make the change urgently.

Personally I think ……..

I look forward to being able to eat …(add your examples e.g. protein, flour, hulled seed, ice cream, milk, cheese, breads, smoothies etc).. hemp seed foods

I look forward to starting my business making …(examples).. hemp seed foods

Finally we will have access to hemp seed foods, thank you

Get the tweak allowing us to have hemp seed foods done with urgency, we have waited long enough

The industry needs access to hemp seed foods don’t wait any longer

A simple tweak to the Food regulations will allow us access to hemp seed foods, get on with it

Don’t let MOH slow us down.

The food issue should be treated separately to the fit for purpose review, as the food is a priority and can be achieved without tweaking the iHemp Regulations.

 

Regrading the “Fit for purpose” review

Yes there are some tweaks that would help the iHemp regulations to work better, but they need to be made in consultation with Industry and should not hold up the Food issue.

The proposed changes to the objectives and interpretations of the iHemp Regulations are not acceptable

Many of your changes are not required as the regulations are fit for purpose

Engage with industry to find out what if any changes are required

The objective and interpretations are clear, the Ministry of Health simply needs to follow the regulations and enable our industry.

Public Newsletter April 2018

Public Newsletter April 2018 – LINK

NZ Hemp Industries Association Inc

Public Newsletter for April 2018

In this issue:

  • The iHemp Summit, Wellington, 5 & 6th July 2018

  • Why are we controlled by the Misuse of Drugs Act 1975

  • Local Events

  • International Events and iHemp Press Articles

New Zealand’s inaugural – iHemp Summit – 5th to 6th July, venue changed to Wellington.

The number of tickets is limited, so get in now to ensure you don’t miss out on the first iHemp Summit in New Zealand.

Stakeholders and interested parties from a wide range of back grounds are going to gather in Wellington to hear from local and international industry experts about the current and future uses of iHemp.

How we can realise the potential of iHemp in the food, fiber and medical industries, what are the road blocks and how we can overcome them.

Introducing common terminology and a vision for the industry, developing a R&D road map and working collaboratively to create a world class industry for New Zealand.

We have the talent and resources to really add value and bring industrial hemp into the 21st century.  We need to catch up, as 80 years of being outlawed means not a lot of work has been done in this space.

Kiwi ingenuity, our unique land and environment have a lot to offer this emerging world wide industry.

We just need to embrace this incredible opportunity,  focus on it and make it happen.  There are huge benefits for our rural communities with jobs and investment in capacity, our economy with export earnings and the production of great products and services.  And our environment by growing a sustainable annual crop

Check out hempsummit.nz  and face book hempsummit.nz

Please pass this on to people in your networks who should be aware of iHemp and the event.

Larry’s Creek Farm – Reefton, West Coast – Harvest 2018

Why are we controlled by the Misuse of Drugs Act 1975 (MODA) – time to bring us in to the 21st Century.

Low THC industrial hemp should not be a controlled drug, as it has no psychoactive properties

In 1975 MODA should have recognised the United Nations Single Convention on Narcotic Drugs, 1961 –  Article 28.2 “This Convention shall not apply to the cultivation of the cannabis plant exclusively for industrial purposes (fiber and seed) or horticultural purposes.”

Clearly MODA is all about controlling THC, the psychoactive cannabinoid in cannabis, they should have specified this rather than classifying all parts of cannabis (including the seed) as a controlled drug.

Both of the above would have simplified things for the iHemp industry as we would be treated as just another arable crop!  And the nonsense of being controlled by the badly worded and out of date MODA legislation would have been avoided.

The constant reference to Misuse of Drugs Act (Industrial Hemp) Regulations 2006, or Misuse of Drugs Act (Medicinal Cannabis) Amendment Bill, is a nonsense and sends the wrong message.

We have regulations for iHemp and soon will have them for medicinal cannabis, these regulations should be controlled by agricultural and medicinal legislation respectively.  And be administered within these frameworks, rather than constantly being referred back to MODA, when the vast majority of “hemp and medicinal products” do not contain any appreciable amounts of THC.

We have the industrial hemp regulations which protect our industry, as only “industrial hemp” can be used to make “hemp products”, and the same regulatory framework approach can be used to allow “medicinal products”

We are not misusing drugs, low THC industrial hemp cannabis is a food and fiber crop and as a medicine, it is very safe with no lethal dose, so how can it be misused when it has been prescribed.

Any cannabis with a higher THC content used as a medicine, would need to be acknowledged by MODA but the actual production and distribution should be covered by the Medicines Act, the same as all other medicines.

Larry’s Creek Farm – Kompolti hemp – West Coast – March 2018

A Local event in Marton, Thursday 23 May 2018
10 am – 12 pm, Farmsource, Wellington Rd

Due to demand, Tom Welch, from Cannock Harvest, will be holding a discussion about growing industrial hemp for interested people at Farmsource, Marton, 10am Thursday 3rd May.

“Covering practical aspects from licence procedure to possible returns etc. If you are interested, pop in for a coffee and converse. We will not have all the answers but are very happy to share what we have learnt in our first year growing the crop. Please indicate if you would like to come along so we can have an Idea on numbers. See/like Cannock Harvest Face Book page for more details. See you there. Tom”

International Events 

International Conference of the European Industrial Hemp Association (EIHA) 12-13 June 2018, Cologne, Germany

The Pacific Rim Hemp conference, 18-19 July 2018, Vancouver, Canada

Hemp Health and Innovation Expo and Symposium 12-13 May 2018, Sydney, Australia

The Miss Use of Drugs – Medicinal Cannabis Amendment Bill
Hear the submissions on the Health Select Committee Facebook page

Recent iHemp – New Zealand press articles

20 Apr 2018 – Budding hemp industry set to grow
20 Apr 2018 – Economic benefits of growing hemp in Northland under spotlight tonight
20 Apr 2018 – $4.20 coffees at Dunedin’s newly-opened Cannabis Museum
5 Apr 2018 – Government asked to widen marijuana bill by New Zealand Drug foundation

31 Mar 2018 – Trio taking $5m bet on medicinal cannabis industry that doesn’t exist yet
17 Mar 2018 – Kiwi company’s big bet on hemp starting to reap rewards
22 Mar 2018 – Cannabis should be decriminalised and taxed to pay for synthetics and meth treatment, says justice advocate
7 Mar 2018 – New Zealand’s plants may give us unique advantages

International News

13 Apr 2018 USA – HIA applauds Senate introduction of the Hemp Farming Act, S. 2667 will clarify many issues facing the US hemp industry.

Join the NZHIA for more information and support for your hemp enterprise, together we stand!

iHemp Summit – goal, speakers and draft program information – April 2018

Goal of the summit

NZ can be the best in the world at growing & using hemp.  This summit will provide NZ companies, farmers, scientists, funders and regulators with the information they need to collaboratively develop the NZ industrial hemp economy. The summit will share local and international knowledge on hemp, identify the local and export opportunities available to companies entering the industry, highlight the barriers to success within the market and develop strategies and relationships that will help the industry to overcome them.

See the draft program outline at hempsummit.nz

Speakers committed to date

Speaker Intended Topic
Mack McIntosh – NZHIA Chair 

 

20+year perspective of the NZ industry

 

Bob Doyle – Managing Director, Hemp International Australia (Australia) Growing, harvesting and processing hemp for fibre
Phil Warner – Managing Director, Ecofibre (Australia) A vision for hemp in New Zealand
Manu Caddie – Managing Director, Hikurangi Group Experiences of NZ’s first medicinal cannabinoid company
Professor Kim Pickering – University of Waikato Emerging R&D on hemp fibre composites
Steve Saunders – Founder and Owner, Plus Group Models for raising investment
Renata Hakiwai – Director, Whenua Kura Skills and training for the hemp economy
Stephen Tallon – Callaghan Innovation Optimising extraction using supercritical CO2
Nick McMillan – Extraction expert Options for extraction of plant extracts from hemp
Anna Campbell – Managing Director, AbacusBio Plant genomics and breeding programmes
Andrew Gibbs – Partner, Deloitte  The economics of growing hemp for medicinal production
Simon Rowell – Founder, Innovation Liberation Front Maximising the value of IP
Carmelle Riley – Whenua Kura Maximising the value of hemp for the Māori economy
Dr Mike Nichols Phytoremediation and growing medicinal cannabis
Dr Margaret Davidson – Western Sydney University (Australia) Health and safety in hemp cultivation and processing

 

 

 

 

The table below provides a draft summary of planned sessions.

Planned Sessions Planned Speakers and Summary
Vision for the Hemp Industry Drawing from international perspectives and experiences, the Summit will begin by presenting a vision for what the future of the hemp industry could look like, both locally and globally.

 

Introduction to Hemp – a New Zealand perspective This session will present opportunities for hemp in NZ based on the experiences of other countries, focussing on products that can be produced now for established global markets. It will also provide various perspectives on the potential future value of the hemp industry to NZ, socially, environmentally and economically.

 

Industry Economics Part 1 – how can NZ create a competitive advantage? This session will provide an overview of the economics of hemp production for food, fibre and medicine and identify potential export opportunities. It will also aim to offer perspectives on global industry dynamics, the competitive positions of other countries and how NZ could create a unique position.

 

Industry Economics Part 2 – what does the ideal industrial hemp value chain look like? A facilitated session that will seek engagement from the delegates to understand what the industrial hemp value chain in NZ currently looks like. This will be followed by again sourcing ideas from the delegates to identify gaps and growth areas, and create a vision for the value chain that will create maximum impact for NZ.

 

Industry Economics Part 3 – maximising the value of hemp for the Māori economy A discussion on potential approaches and models for maximising the value of hemp across the Māori economy.
Moving to Hemp Part 1 – growing and harvesting industrial hemp The Moving to Hemp block sessions will begin by discussing local and international experiences in converting land for hemp production. The aim of this session will be to provide insights into: the requirements for cultivating hemp in the NZ climate, regions that are best suited to cultivation and plant variety selection and specific cultivation/harvesting techniques for food, fibre and medicine applications. It will also cover the latest information on plant breeding in NZ.

 

Moving to Hemp Part 2 – plant science and cultivar selection
Hemp for Fibre An overview of techniques for cultivating, harvesting and processing hemp for fibre production, as well as a summary of current and future product opportunities and emerging research areas.
Hemp for Food An overview of current opportunities and barriers for the use of hemp seeds and oils in food products. The session will aim to cover the health benefits of hemp products and facilitate discussion on potential high value product opportunities based on global trends.

 

Hemp for Medicine This session will provide an overview of that latest science on the efficacy of cannabinoids in medicine and discuss key considerations for cultivation and extraction.

 

Filling the Value Chain Gaps Part 1 – the importance of skills and training A discussion on the importance of skills development and training in creating a new emerging NZ industry.

 

Filling the Value Chain Gaps Part 2 – the value of intellectual property An introduction to the IP protection and licensing principles that will be relevant across the NZ hemp value chain and how these can be best used to support and protect our unique position.

 

Filling the Value Chain Gaps Part 3 – health and safety in hemp cultivation A discussion on potential health and safety considerations for the emerging hemp industry and provide insight into methods for developing best practice guidelines for growers and manufacturers.
Filling the Value Chain Gaps Part 4 – models for raising investment This session will focus on key considerations and potential models for raising funds in the New Zealand funding and investment environment.

 

 
Summit Dinner Day One will close with a Summit Dinner in the evening, providing a valuable opportunity for networking and building connections to support New Zealand’s emerging hemp economy.

 

 

 

 

Medical Cannabis – M A Nichols – November 2017

 

LINK – MEDICAL CANNABIS Dr Mike Nichols 07.11.2017

Medical Cannabis   – 7 November 2017

  1. M. A. Nichols1

110 Newcastle St, Palmerston North 4410, New Zealand.

Abstract

The medicinal use of cannabis is not a new, as until the 1930’s cannabis was a regular component in the chemist’s arsenal against pain. At about that time cannabis use was essentially banned in the USA, and eventually throughout the world. Things have now changed, and there has been a general relaxation of the law, particularly in the USA and Canada. Australia and New Zealand are likely to follow the general world-wide trend, but how best to grow the crop for medical purposes has yet to be determined. In this presentation I will provide an introduction to the various types of cannabis, examine some of their different medical properties, suggest how they might be best grown for medical purposes, and consider possible methods by which the cannabinoids are ingested.

 

Keywords: cannabinoids, thc, cbd, medicinal

INTRODUCTION

There has been considerable interest recently in both Australia and New Zealand regarding the possibility of using cannabis for medicinal purposes. Early in 2015 the Norfolk Island Government approved the growing of medicinal cannabis on the Island, but this decision was rapidly countermanded by the Australian Federal Government in Canberra. It now appears that it is only a question of time before the Federal (and State) Governments in Australia will approve the growing and selling of cannabis for medical purposes. In November 2015 it was announced by the Turnbull government that they will introduce a national scheme to legalise medicinal cannabis by licensing growers, which could pave the way for a local industry. Health Minister Sussan Ley said that the government had drafted legislation to establish a single scheme for growers in all states and territories, which would be introduced in Parliament’s early in the next year. Both the Victoria and NSW State governments have previously indicated they want to legalise medicinal cannabis, and are waiting on a federal regulatory scheme.

The medicinal use of cannabis is not a new use for the plant, as until the1930’s cannabis was a regular component in the chemist’s arsenal against pain. At that time cannabis was banned in the USA, although the true reasons are unclear but suggestions are that:

  • the hemp fibre was too competitive with the new artificial fibres developed by Du Pont
  • The psychoactive drug was resulting in the rape of nice white American girls by Mexican emigrants
  • It was to find employment for the many inspectors who had previously been employed with the alcohol prohibition.

Whatever the reason, it is clear that during the 41-45 war the USDA strongly promoted the growing of cannabis (as hemp) for the fibres as anchor ropes etc, but as soon as the war concluded all the booklets on how to grow the crop were pulped, and the USA (via UN) promulgated the banning of cannabis world-wide for all purposes. A move which New Zealand went along with, and essentially only a few countries particularly those behind the “iron curtain” did not.

So what is cannabis?

 

 

Arguments still exist regarding the precise botanical classification of the plant, as to whether it is Cannabis sativa or Cannabis indica (or even Cannabis ruderalis) but for the purpose of this article we will only classify it according to uses. Essentially these are:

Industrial Hemp

A low THC type which is used for fibre (it is the world’s strongest natural fibre) or for the oil produced in it’s seed or as a “mop crop” for absorbing waste water nutrients from sewage plants or freezing works.

Medicinal cannabis

A high THC type which is used for pain relief or a high CBD type which is used for epilepsy (and other nervous) problems.

Recreational cannabis (marijuana)

A high THC type which is used recreationally as a psychoactive drug.

All the above types are generally considered to be either the species Cannabis sativa or Cannabis indica, or a cross between the two species.

MY INTRODUCTION TO CANNABIS

My involvement with cannabis started in 2001 when I was invited to become the Research Team Leader for the NZ Hemp Industries Association (NZHIA), and as a result I found myself learning now only about hemp, but also about medicinal and recreational cannabis production, leading to a meeting with the management team of GW Pharmaceuticals in London, and a visit to the Bedrocan medicinal cannabis growing operation in the Netherlands. The only 2 organisations legally growing medicinal cannabis in the world at that time.

Recently there have been major changes, with about half the States in the USA allowing the growing of medicinal cannabis, and some (4 at present) allowing the legal growing and use of cannabis for recreational purposes

It is to be hoped that if we (Australasia) are to develop an export industry with medicinal cannabis, that the necessary research will be undertaken in order to establish the most efficient method to produce a high quality product.

The Australian Scene

No doubt this has been stimulated by the donation of $AU 33.7 million by Joy and Barry Lambert to fund medicinal cannabis research at Sydney University. Clearly in the future Australian medicinal cannabis research will become mainstream with that sort of backing.

The New Zealand scene

In a recent survey there was general agreement that recreational cannabis use should be decriminalised, however the water in relation to medicinal cannabis use was not considered, and government is against any relaxation of the current laws regarding cannabis recreational use.

Research on medical cannabis

In fact there has been very little research worldwide on either the production of medicinal cannabis, or on the medicinal properties of the different cannabis strains.  GW Pharmaceuticals (www.gwpharm.com), are probably the leading company in terms of researching the clinical aspects of cannabis, but they do not appear to have undertaken much in terms of cannabis production research. The other major company (Bedrocan – bedrocan.nl) are really a production company and did not appear to have a research arm. Their production is in a plant factory with lighting provided by fluorescent lights (young plants) and by High Pressure Sodium lights (HPS) for mature plants. The only published research work on the production of non hemp cannabis (ie medicinal/recreational) in a “plant factory” has been by a research group in Belgium who demonstrated that plant density played a role in productivity, and that there were some genetic differences, and that in general terms 1 g of dried cannabis head was produced for every 1 watt of HPS electrical light used. (Vanhove et al., 2011; Vanhove et al., 2012.) The project undertaken by ESR in New Zealand was more in the realm of lets grow some high THC cannabis and collect some data. (Knight et al, 2010).

Apart from these three studies there are not any peer review scientific papers on how best to produce medicinal cannabis, although the web offers a huge amount of information (of uncertain reliability) on the growing of cannabis either for recreational or for medicinal purposes. No doubt the commercial producers of medicinal cannabis in both Canada and USA have research programmes, but these results are likely to remain in-house.

What is cannabis

Essentially cannabis is a complex plant in terms of it’s medicinal properties as it contains both THC (Δ9 tetra hydrocannibinole) and CBD (cannabidiole) along with a large number of other cannabinoids and terpenes, which may also have medicinal properties.

In very simplistic terms the level of THC determines the pain relief properties of the plant, while the CBD level has a major influence on the effect of cannabis on the nervous system. However, it is clear that both have a synergistic effect on the other, along with the effect of the many other cannabinoids. There are strong opinions that cannabis can have valuable effects on a wide range of medical conditions, and there is a real danger of it being considered a panacea for all human ailments. We have a lot to learn.

Dravet’s syndrome (a severe, intractable, and eventually fatal, childhood form of epilepsy) appears to be ameliorated to some extent by the use of high CBD cannabis types, of which the selection of the variety called “Charlotte’s Web” appears to have a strong following. This one plant is believed to be one of the tipping points in the decision to make medicinal cannabis an acceptable medicine in USA, and thus open the door to similar decisions in other countries. In fact, 23 US states now permit the use of medicinal cannabis, and 4 states actually permit its use for recreational purposes.

Professor Lyle Craker of the University of Massachusetts has argued strongly for over 20 years for approval to grow cannabis for medicinal purposes, but has continually been turned down by the US Federal Government. A decision was then made to allow the plant to be grown under local (State) law, with it still being a prohibited plant under Federal law!!! Funny old world. The genie is well and truly out of the bottle.

It is now generally considered that cannabis is a far safer “drug” than alcohol, and that if alcohol was invented now, it would certainly be on the prohibited list!!!  Note: this is NOT a suggestion to legalize recreational cannabis use, or to promote alcohol prohibition simply a known fact.  It is an interesting fact that in New Zealand the producers and purveyors of alcohol may receive knighthoods, while the equivalent cannabis suppliers may receive a prison sentence!

In Canada, where medicinal cannabis is now legal, one producer (Aphria) in Leamington (Ontario) already has 2/5 ha of greenhouses growing high quality medicinal cannabis, and has plans to double this area in the near future. Currently they grow 12 different varieties which range in drug content from 22% THC and 0% CBD to 1.4% THC and 9% CBD. This is sold for about $NZ9.00/g, substantially lower (about half) than the price of illegal high THC cannabis in New Zealand.

Medicinal tests of cannabis

For most (all?) medicinal drugs there is a standard procedure for testing which involves, initially animal tests, followed by human tests. With the objective of determining the sort of response the population will have to different levels of the drug.  These are then followed by blind and later double blind clinical tests in which the patient does not know whether they are receiving the drug or a placebo, or the more robust double blind test in which the doctor does not know also.  This is the procedure used by GW Pharmaceuticals for their research.

I am not aware of any such tests being undertaken in USA, and as GW Pharmaceuticals produce only a single THC based medicine (Sativex) and a high CBD based experimental medicine (Epidiolex) and some (many?) North American medicinal cannabis growers provide a wide spectrum of THC/CBD levels in their product, it is difficult to see the North American situation fitting into the Australasian medicines requirements. It appears to be more similar to that of a herbal medicine.

Delivery of the drug

Aphria have recently received approval to develop a cannabis oil, which will allow the production of capsules containing precise quantities of THC and CBD. In this respect they differ from the UK producers (GW Pharmaceuticals) (www.gwpharm.com) who dispense their medicinal cannabis via a buccal spray, or the Dutch producers (Bedrocan) who use a vaporizer. Generally in North America smoking (as in recreational cannabis) appears to be the norm.  Aphria (www.aphria.com) are developing a cannabis oil for oral consumption.

Growing medicinal cannabis

If we are to establish a medical cannabis industry in Australasia we have to establish sound horticultural growing methods to maximise the yield of the desirable chemicals. Growing medicinal cannabis in a greenhouse has significant cost advantages compared with plant factory production, but requires considerable specific skills to ensure freedom from pests and diseases (an important factor in any medicinal product). In addition it is essential to have the sort of knowledge of day length control (such as the year round chrysanthemum growers have), as flower production in cannabis requires short days. This is much easier to achieve in a plant factory, fully lit by artificial lights, but the current knowledge is mainly with using High Pressure Sodium (HPS) lamps, and knowledge on how best to make use of LED lights for cannabis production is still to be fully explored..

For example we know that the drug content is likely to be enhanced by the use of UV B light close to harvest, but it could well be that other specific wavelengths could also have a marked effect on the level of drugs produced in the plant.

Plant factories also have the advantage that (potentially at least) they can be made relatively free from pests and diseases, by ensuring that only filtered air enters the factory, and that there is always a positive pressure inside the room. The use of any pesticides is a not a good idea for any crop to be used for medicinal purposes!!

So what are the basic principles to consider when growing medicinal cannabis?

 

Growing medicinal cannabis 101

For a start it must be noted that although it is possible to grow medicinal cannabis from seed it is very important to have the right variety, and this means that clonal propagation is essential. This means that it is necessary to grow the plants from cuttings, which must be produced on “mother” plants which are grown under a non-flowering (long day) regime. The second important factor is that the drug content is found predominantly in the un-pollinated female flower heads. Fortunately with very few exceptions cannabis plants are dioecious (it has distinct male and female plants), so if you take cuttings only from selected female plants you will have only un-pollinated flower heads.  The third fact to note is that cannabis is similar to chrysanthemums, in that it remains vegetative under long days, and requires short days in order to flower, and remains vegetative in long days (over 12 hours).

This means that we need to have two distinct sets of plants, namely: –

  • Mother plants, which are grown in long days to ensure that the cuttings they produce are vegetative
  • Cropping plants which start off initially as cuttings and then at some later stage in growth are given short days to ensure that they produce flower heads.

In the field, cannabis will only flower in the autumn, and so we will only obtain a single crop per year. If we grow in a greenhouse it is possible to achieve 3 crops per year, by using artificial lighting to give the required long days (for vegetative growth) during the winter months, and black out curtains to provide short days (for flowering) during the long days in the summer. Thus we can make the plant believe that it is whatever season we wish. This is similar to the production of year round chrysanthemums.

Of course if we grow in a plant factory, entirely under artificial lights, then these conditions can be applied simply by means of a time clock.

The next question is how best to grow the plants, after the cuttings have been produced (and rooted)?  Soil is not a good medium in which to grow plants, and the New Zealand police actually categorize the intensity of an illegal cannabis crop in terms of whether it is soil grown or hydroponic. Growing hydroponically is considered to demonstrate greater skill, higher yield and therefore greater culpability.  Nutrient film technique (NFT) is considered to demonstrate the greatest skills, although personally I suspect that an ebb and flow system using a growing medium might in fact be superior.

There are a very real number of questions that still remain unanswered in relation to medicinal cannabis production, such as:-

  • What is the optimum plant density?
  • How long should the plants be grown vegetatively before initiating flowers?
  • What is the optimum temperature?
  • What is the optimum lighting? Intensity, wavelength
  • And of course is greenhouse production more efficient than using a plant factory.

It should be noted that plant factories for cannabis really only developed in order to hide the operation from the police.

Medicinal cannabis production research

The only published high THC cannabis research carried out in New Zealand was by Knight et al (2010) of the Crown Research Institute of Environmental Science and Research (ESR), who grew 3 crops. Because of their acknowledged lack of horticultural skills they used a previously convicted cannabis grower as a consultant. Only the first crop performed to a reasonable standard, as the second crop succumbed to spider mite, and the final crop also had some problems. The value of her research from a scientific point of view is doubtful, as little (no) information is provided about the growing environment or even in fact the actual plant density being used. All the results are only of the yields per plant. This was at the request of the police.

The two Belgium studies, undertaken at the University of Ghent at the request of the Belgium police is much more forthcoming. They provide us with information on different cultivars and plant densities, and of course the yield of dried heads from the different treatments. Undertaken from a recreational drug view point, the information obtained is likely to be relevant not only for high THC medicinal cannabis production, but also for the production of high CBD medicinal cannabis. All the results to date suggest that the yield of dried cannabis head approximates to 1g for every watt of power used in lighting.

The downside of the Belgium study is that the light source was High Pressure Sodium lamps (HPS), and these are being rapidly supplanted with LED lights, which are cooler, much more efficient and with far long life. With our present state of knowledge LED’s should be used at a 4:1 ratio of red/blue, along with a small amount of “white” light, but this is something that I am sure our North American friends are investigating under the legal production regime that exists in much of North America.

Literature cited

Knight G, Hansen S, Connor M, Poulsen H, McGovern C & Stacet J (2010). “The results of an experimental indoor hydroponic cannabis growing study, using the `Screen of Green’ (ScrOG) method–Yield, tetrahydrocannabinol (THC) and DNA analysis”, Forensic Science International, 202(1-3), 36-44

Vanhove, W, Van Damme P, & Meert, N. (2011) “Factors determining yield and quality of illicit indoor cannabis (Cannabis spp.) production” Forensic Science International, 212 (1-3), 158–163

Vanhove, W, Surmont. T, Van Damme P, & De Ruyver, B.  (2012) “Yield and turnover of illicit indoor cannabis (Cannabis spp.) plantations in Belgium”. Forensic Science International. 220 (1-3), 265–270

 

 

Public Newsletter March 2018

Public Newsletter March 2018 – LINK

 

NZ Hemp Industries Association Inc

Public Newsletter for March 2018

In this issue:

  • The Medicinal Cannabis Bill – Submissions close 21 March 2018 – 9 Days to go

  • Hemp Summit, July 5 &6 th 2018

  • Enabling the industry

  • A petition requiring support & recent iHemp articles 

The NZHIA encourages you to make a submission on the Misuse of Drugs Act (Medicinal Cannabis) Amendment Bill.

For further information on how to make a submission and what to include please visit our websiteNZHIA.com

This is a very important issue to many industry participants and we encourage you to make sure your voice is heard on this topic.

When making a submission it is important to stress that the Medicines Bill should not impact on the Industrial Hemp Regulations 2006.

It should be noted, that if you have some personal experiences of the efficacy of Medicinal Cannabis as a patient, carer, family member, physician.  It would be useful for the Select Committee to hear, as they may not know much about the range of patients it helps, how it benefits them and how it is currently used, in an illegal unregulated environment.

We all need to encourage other people/organisations (patients, carers and medical professionals) to make a submission and make their comments and recommendations count.

Hon Dr David Clark – press release 20 December 2017

The Misuse of Drugs Amendment Bill being introduced today will:
•    Introduce a medicinal cannabis scheme to enable access to quality products
•    Introduce a statutory defence for terminally ill people to possess and use illicit cannabis
•    Remove cannabidiol from the schedule of controlled drugs

“In time, this legislation will result in a greater supply of quality medicinal cannabis, including products made here in New Zealand.

“However, there will be people who can’t wait. So as an interim measure the legislation will create a legal defence for possession and use of illicit cannabis for people who are expected by their doctors to be in their last year of life. This does not make it legal for the terminally ill to use cannabis, but it means that they will not be criminalised for doing so.

“New Zealanders are a compassionate people. Medicinal cannabis products can help ease suffering and we should make it easier for people to get them.”

The Hemp Collective – Hastings 2018 facebook.com/hempcollectiveltdnz,
instagram.com/hempcollectiveltd         www.hempcollective.co.nz

The First New Zealand – iHemp Summit – 5th to 6th July, Palmerston North.

Thank you for the positive response from our hold the date email we have sent to you all.

We are planning a world class event and need you to be involved.

The event will cover a range of topics relevant to the iHemp industry, from people that have “been there and done that” the outcome will be a R&D road map and vision for our future industry.  We will be raising awareness of the road blocks and how to overcome them.

We will be sending more publicity from www.hempsummit.nz over the next few weeks

Please pass this on to people in your networks who should be aware of iHemp and the event.

If you Cc admin@hempsummit.nz on your emails and we will follow up

Hemp Collective – Hastings 2018

Enabling Primary Industry

At the Australian Industries Association convention in Geelong last month, there were Agriculture Ministers and Regulators present, in the audience and presenting.

The Agricultural Ministers were very supportive and eager to help enable and facilitate the industry.

Government support has been incredible compared to us in New Zealand.

There seed industry scaled up over the summer season and is set to supply much of the local demand for food products, having had access to this market since November last year.

While we have to wait until maybe October to hear when we can sell hemp foods for humans

These are all examples of how a supportive government can enable primary industry.

The current coalition government is in a prime position to make this happen and allow our NEW industry to grow, with sustainable and positive benefits for our farms, rural communities, manufacturing, food, technology and many other sectors of the economy.

all based on the growing and production of a wide range of goods and services for local and international markets.

iHemp ticks all the right boxes and such a positive industry needs to be enabled as was the intent of our iHemp regulations 2006.

Hemp Collective 2018 – Bees enjoying the pollen from the male flower

A Petition requiring support

Raising publicity is always hard to do for any new industry,  Chris Woodney from NZ Hemp Brokers, has created an online petition to highlight some issues we face and how the government need to “enable” our industry as per the object of the industrial hemp Regulations 2006.

With 6,000 signatures so far, it shows great support for our industry. Please consider signing the petition at Change.org

Hemp is not a Drug Remove industrial Hemp from the Misuse of drugs act MoDA 1977

Recent iHemp articles

11 Mar 2018 – Kiwi Innovation can make us world leaders in medicinal cannabis
21 Feb 2018 – Law changes may triple hemp plantings
11 Mar 2018 – Medical marijuana a “billion dollar industry” says exporter who employs staff with a past
23 Feb 2018 – $160M Kiwi cannabis export deal to US
2 Feb 2018 – Medicinal cannabis centre set to open in West Auckland
26 Jan 2018 – New Zealand’s only cannabis company plans to crowdfund for clinical trials

And one not so recent – but very relevant 
 3 March 2016 – New Zealand urged to grow cannabis for medicinal pur

Medicinal Bill Submissions Due 21 March 2018

NZHIA Encourage you to make a submission on the Medicinal Cannabis Bill before 21 March 2018

Useful documents  (links in green or bold)

The proposed bill is the start of a process whereby a “medicinal Cannabis Scheme” will be created to act as a framework to allow for the regulated import, production, supply, prescription and consumption of medical cannabis products to patients.

This will be administered by a yet to be established “government agency for domestic production of medicinal cannabis”

Currently only CBD products have been defined and removed from control as a class B Drug, but they may still be controlled as a class C Drug.  Medicinal cannabis products containing THC seem to have been left out of the Bill.

To make a submission click here, be prepared to give your details and make comments and recommendations to the Health Select Committee on the Medicinal Cannabis Bill

The Drug Foundation – Making a submission covers how to make a submission and a range of topics to consider

NZHIA Key points

  • Fair and compassionate approach, would allow access to more than just the terminally ill
  • Urgency to get this set up as soon as possible, as patients are already using it and more would do so if it was affordable, available and legal
  • Wider industry consultation is required when establishing the Scheme, as currently the bill does not cover local production
  • Hemp products with naturally occurring cannabinoids must be exempt from inclusions as medicinal products
  • We need more detail on the ”medicinal cannabis scheme”, what products will be covered, how will they be locally sourced and what protection from prosecution will patients, care givers, prescribers, producers and growers have
  • The effect of medical “CBD products” on the “hemp products” contained in the Industrial Hemp Regulations 2016. CBD will no longer be a controlled drug, will this include all other cannabinoids (excluding THC) and their acid precursors

For further information on what to include in your submission, check out

The Health Select committee is made up of:

  • Chair Louisa Wall – Labour
  • Deputy Shane Reti,-  National
  • Jonathan Coleman – National
  • Liz Craig – Labour
  • Matt Doocey – National
  • Anahila Kanongata’a-Suisuiki – Labour
  • Nicky Wagner – National
  • Angie Warren-Clark – Labour

1 2 3 5